Highly Potent Active Pharmaceutical Ingredients Conference 2023

The Global High Potency API/HPAPI Market is projected to reach 37 billion USD by 2027, growing at an ever-increasing CAGR of 8.43%. The expanding production of high potency APIs, along with the increase in associated toxicities, are driving requirements for more effective containment solutions and much-needed guidelines to ensure worker safety.

Our 2023 conference brings insights from leading pharmaceutical companies on how to improve hazard identification, integrate advanced containment controls and mitigate the risk of manufacturing HPAPI. Featuring leading speakers including directors, engineers, and experts in validation requirements this conference provides an extensive look at how you can futureproof your pharmaceutical manufacturing facilities.

This two-day conference offers you peer-to-peer networking with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more. Expand your community and explore the latest developments in the industry at this two-day event, including key regulatory updates, and leading case studies from leading pharmaceutical and biotechnology companies.

Benefits of Attending the HPAPI Conference:

  • LEARN how to ensure advanced therapeutic manufacturing is safe for workers and patients
  • INCREASE the effectiveness of your engineering containment controls by improving harmony between the worker engineer and toxicologist to ensures cost-effective design choices
  • UNCOVER the best practises & opportunities for pharmaceutical companies to work alongside CMOs to effectively and efficiently scale-up HPAPI manufacturing
  • REVIEW case studies on the implementation of risk-based hazard identification strategies from leading pharmaceutical companies including AstraZeneca, CSL Behring and Merck

DISCOVER future trends in containment and control technologies to future-proof your HPAPI manufacturing plant to maximsie operator safety

To know more visit: www.highlypotentapi.com/PharmaJournalistEL

Comments (0)
Add Comment